A new treatment for arrhythmia
Nature Medicine
March 30, 2009
A drug currently available in the clinic could be used to treat patients with an inherited form of cardiac arrhythmia, according to a study published this week in Nature Medicine.
CPVT―a specific type of ventricular tachycardia―is a potentially lethal form of arrhythmia. It is commonly linked to mutations in cardiac calcium channels known as ryanodine receptors. Pharmacological interventions against CPVT are often ineffective, but Bj?rn Knollmann and his colleagues have now found that flecainide―a drug already approved to treat other arrhythmias by acting on sodium channels―prevents disease in a mouse model of CPVT by a new mechanism: the direct inhibition of calcium release mediated by cardiac ryanodine receptors.
Flecainide also prevented CPVT in two patients who had not responded to conventional drug therapy, indicating that this currently available drug is a promising mechanism-based therapy against this condition.
doi: 10.1038/nm.1942
Research highlights
-
Jun 30
Genomics: Gray wolf genome hints at dual ancestry of dogsNature
-
Jun 30
Evolution: Hawks learn on the fly to swoop up before perchingNature
-
Jun 30
Microbiology: Transmission of gastrointestinal viruses in salivaNature
-
Jun 29
COVID-19: Assessing instances of long COVID in UK health dataNature Communications
-
Jun 24
Palaeontology: It sucked to be the prey of ancient cephalopodsScientific Reports
-
Jun 24
Sport science: New wearable sensor to measure neck strain may detect potential concussionScientific Reports